Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported ...

Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual riskSALT LAKE CITY, May 07, ...

Q1 2025 Earnings Call Transcript May 6, 2025 Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $-0.03, ...

First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year ...

Myriad Genetics faced a challenging Q1 2025, impacted by GeneSight volume declines and slower-than-expected hereditary cancer testing. Revised guidance reflects these headwinds, but management ...

Myriad Genetics, Inc. announced in a press release ... risk scores in their management decisions. Myriad's MyRisk® Hereditary Cancer Test, which assesses multiple genes, provides personalized ...

About MyRisk ® Hereditary Cancer Test with RiskScore ... breast cancer risk assessment individualized to them. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing ...

About MyRisk® Hereditary Cancer Test with RiskScore ... breast cancer risk assessment individualized to them. Myriad Genetics is a leading molecular diagnostic testing and precision medicine ...

Q1 2025 Management View CEO Sam Raha opened the call by highlighting a challenging Q1 2025, with revenue of $196 million, ...

Myriad Genetics does not provide forward-looking ... reflecting an updated outlook for our pharmacogenomics business and hereditary cancer testing in our Women's Health business.